Characterization of a Novel Venetoclax Resistance Mutation (BCL2 Phe104Ile) Observed in Follicular Lymphoma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16069
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma

Cancer Discovery
Oncology
2017English

Targeting BCL2 With Venetoclax Is a Promising Therapeutic Strategy for "Double-Protein-Expression" Lymphoma With MYC and BCL2 Rearrangements

Haematologica
Hematology
2018English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2016English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Follicular Lymphoma

Nature Reviews Disease Primers
Medicine
2019English

Characterization of Intratumoral Follicular Helper T Cells in Follicular Lymphoma: Role in the Survival of Malignant B Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Follicular Large Cleaved Cell (Centrocytic) Lymphoma: A Distinctive but Unrecognized Variant of Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Unraveling Tumor Heterogeneity in an Apparently Monolithic Disease: BCL2 and Other Players in the Genetic Landscape of Nodal Follicular Lymphoma

Frontiers in Medicine
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy